Core Viewpoint - The stock of Valiant Pharmaceuticals-B (09887) has increased by over 3%, currently trading at 57.9 HKD with a transaction volume of 20.21 million HKD, following the announcement of research abstracts accepted for presentation at the 67th Annual Meeting of the American Society of Hematology (ASH) [1] Group 1: Company Developments - On November 4, Valiant Pharmaceuticals-B announced that five research abstracts have been accepted for presentation at the 67th ASH Annual Meeting [1] - The company provided further details on its innovative drugs LBL-034 and LBL-076, with multiple research abstracts included in the ASH meeting [1] - One clinical study of LBL-034 has been selected for the first oral presentation on the first day of the conference, showcasing the latest efficacy and safety data for LBL-034 in patients with relapsed/refractory multiple myeloma [1]
港股异动 | 维立志博-B(09887)涨超3% 5项血液肿瘤领域研究成果于2025 ASH年会公布